Transactivation of human PXR transfected in HepG2 cells assessed as CYP450 induction by measuring fold activation at 10 uM by luciferase reporter gene assay
Invivo inhibition of MAT2A in human HCT116-MTAP null cells xenografted po dosed nu/nu mouse model assessed as plasma exposure required for reduction in tumor SAM level
Invivo inhibition of MAT2A in human HCT116-MTAP null cells xenografted po dosed nu/nu mouse model assessed as plasma exposure required for reduction in brain SAM level
Inhibition of MAT2A in human HCT116-MTAP null cells xenografted in nu/nu mouse model assessed as reduction in tumor SAM level by measuring EACU50 (0 to 12 hrs) at 0.3 to 10 mg/kg, po administered 2 times QD or 0.3 to 3 mg/kg, po administered 3 times BID and measured upto 24 hrs post last dose
Inhibition of MAT2A in human HCT116-MTAP null cells xenografted in nu/nu mouse model assessed as reduction in brain SAM level by measuring EACU50 (0 to 12 hrs) at 0.3 to 10 mg/kg, po administered 2 times QD or 0.3 to 3 mg/kg, po administered 3 times BID and measured upto 24 hrs post last dose
Ratio of free plasma IC50 for inhibition of MAT2A in human HCT116-MTAP null cells xenografted po dosed nu/nu mouse model assessed as reduction in tumor SAM level to free plasma IC50 for inhibition of MAT2A in human HCT116-MTAP null cells xenografted po dosed nu/nu mouse model assessed as reduction in brain SAM level